Search - tctmd.com

Displaying 1 - 20 of 87

Sort: Relevancy | Date

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

News Conference News EuroPCR 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

May 22, 2025

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

News Conference News EuroPCR 2025

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

Michael O'Riordan

May 21, 2025

Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years

News Daily News

Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years

Yael L. Maxwell

July 22, 2024

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

Big Gains in Function, QoL With Transcatheter TV Replacement: TRISCEND Registry

News Conference News PCR London Valves 2022

Big Gains in Function, QoL With Transcatheter TV Replacement: TRISCEND Registry

November 28, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

TOMAHAWK: Swift Angiography No Benefit in OHCA Without STEMI

News Conference News ESC 2021

TOMAHAWK: Swift Angiography No Benefit in OHCA Without STEMI

August 29, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Trimetazidine Safe but Not Protective Long-term After PCI

News Conference News ESC 2020

Trimetazidine Safe but Not Protective Long-term After PCI

August 30, 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

News Conference News TVT 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Michael O'Riordan

June 23, 2020

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

News Conference News TVT 2020

Sapien 3 in Intermediate Risk: Death or Stroke Similar to SAVR at 5 Years

Michael O'Riordan

June 22, 2020

MitraClip Cuts Death, HF Hospitalization Across NYHA Class: COAPT

News Conference News TVT 2020

MitraClip Cuts Death, HF Hospitalization Across NYHA Class: COAPT

Michael O'Riordan

June 21, 2020

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

September 26, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

September 26, 2019

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

News Conference News EuroPCR 2019

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

May 23, 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

May 16, 2019

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

MITRA-FR: No Benefit of MitraClip in Functional MR

News Conference News ESC 2018

MITRA-FR: No Benefit of MitraClip in Functional MR

August 27, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.